Abstract
Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.
Keywords: atopic dermatitis, dermatology, eczema, JAK inhibitors, tofacitinib
Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.
1. INTRODUCTION
Atopic dermatitis (AD) is an autoimmune inflammatory disease, characterized by xerosis, eczematous lesions, redness, persistent, and severe pruritus. In this case report, we show a different option of treatment for severe, chronic refractory cases.
2. CASE REPORT
A 63‐year‐old man, with a chronic history of severe AD (defined as >10% body surface area involvement and scoring of AD, SCORAD > 20), who had failed multiple systemic therapy. He presented with a history of atopic dermatitis since childhood, which got worse in the past 8 years, increasingly progression with whole body involvement. SCORAD‐66.7% DLQI‐22 (Figure 1).
FIGURE 1.
Before treatment with tofacitinib 5 mg/BID; previous treatments included topical corticosteroids, tacrolimus ointment, moisturizers, prednisone, methotrexate, azathioprine, cyclosporine, antihistamines, antidepressants, thalidomide, and phototherapy
Previous treatments included topical corticosteroids, tacrolimus ointment, moisturizers, systemic therapy with oral prednisone (1mg/kg/daily) and methotrexate, azathioprine, cyclosporine, antihistamines, antidepressants, thalidomide, and phototherapy, all of them with little or no response. His last attempt was with ustekinumab; however, after 6 months it had no improvement.
The patient had a family history of inflammatory bowel disease but denied other autoimmune conditions. Complete review of systems was negative. Physical examination revealed reddish, lichenified plaques involving face, trunk, and extremities affecting approximately 25% of total body surface area (Figures 2 and 3). Given the severity of the disease, the limited and inadequate treatment options, with the patient's concern, we decided to treat with tofacitinib citrate by oral route with JAK inhibitors. At this time, dupilumab was not available in Brazil.
FIGURE 2.
Before treatment with tofacitinib 5 mg/BID
FIGURE 3.
Before treatment with tofacitinib 5 mg/BID
Tofacitinib citrate 5mg BID was started. During the first month, he was still on prednisone 20 mg/daily but it was weekly decreased from 20mg to 10mg, then to 5mg until it was totally suspended. During this period, no topical corticosteroids were used, only moisturizers. After three months of treatment, he had nearly complete clearance of face, trunk, upper and lower extremities (Figures 4 and 5). SCORAD‐10.1% DLQI‐3.
FIGURE 4.
After 3 mo of treatment with tofacitinib citrate 5 mg/BID
FIGURE 5.
After 3 mo of treatment with tofacitinib citrate 5 mg/BID
At 16 months of follow‐up, he had sustained response on maintenance therapy with tofacitinib 5mg/BID. During treatment, patient developed one episode of uncomplicated herpes simplex infection that was treated with valacyclovir. Laboratory monitoring has not revealed abnormalities.
3. DISCUSSION
Atopic dermatitis (AD) is a common, systemic, relapsing, autoimmune inflammatory dermatosis. 1 AD is characterized by xeroxis, eczematous lesions, marked dryness and redness, persistent, and severe pruritus. 2 AD is associated with a high burden: sleep disturbance, anxiety and depression and impair quality of life. 3 The management of atopic dermatitis involves emollients, topical corticosteroids, and calcineurin inhibitors and for refractory disease, immunomodulatory agents, often inadequate for moderate to severe disease. Advances in the understanding of the pathogenesis of AD have allowed new therapeutic approaches.
AD is a predominantly Th2 disease. The key cytokines (IL‐4, IL‐5, IL‐13, IL‐17, IL‐22, IL‐23, IL‐31, IL‐33, and IFN‐y) has a central role in AD pathogenesis, 4 and Janus kinase (JAK), signal transducer and activator of transcription (STAT) and spleen tyrosine kinase (SYK) pathways are involved in signaling these cytokines. In AD, the use of JAK inhibitors is interesting to block both IL‐4 and IL‐13 in acute phase and interferon y (IFN‐y) in chronic phase.
Tofacitinib citrate, an oral JAk1/3 inhibitor approved for the treatment of arthritis rheumatoid, psoriatic arthritis, and inflammatory bowel disease has already been used to treat other autoimmune disease such as alopecia areata 5 , 6 and vitiligo. 7 Here, we report the successful use of oral tofacitinib for a patient with severe atopic dermatitis refractory to all immunomodulatory drugs previously tried.
4. CONCLUSION
Although the use of JAK inhibitors for atopic dermatitis is still off label, oral tofacitinib used for AD has proven to be efficient. In 2015, Levy et al showed efficacy of oral tofacitinib in atopic dermatitis case series. 8 Then, in 2016, Bissonette et al demonstrated good results with topical tofacitinib in a clinical trial. 9 And more recently, clinical trials with new JAK ½ inhibitor baricitinib and JAK 1 inhibitors upadacitinib and abrocitinib resulted in improvement in EASI score of patients. 10 , 11 , 12 , 13 The positive results in case of refractory severe AD suggest that oral tofacitinib can be considered as an therapeutic option. AD is a multifaceted disease so the use of new therapeutic drugs remains an exciting possibility.
CONFLICT OF INTEREST
None declared.
AUTHORS’ CONTRIBUTIONS
Sineida Berbert Ferreira: was involved in direct management of the patient. Rachel Berbert Ferreira: reviewed the pertinent literature, the manuscript, and the final draft. Morton Scheinberg: drafted the manuscript and supervised the final draft.
ETHICAL APPROVAL
The patient agreed with the publication and signed the free and informed consent form.
Berbert Ferreira S, Berbert Ferreira R, Scheinberg MA. Atopic dermatitis: Tofacitinib, an option for refractory disease. Clin Case Rep. 2020;8:3244–3247. 10.1002/ccr3.3325
REFERENCES
- 1. Williams HC. Atopic dermatitis. N Engl J Med. 2005;352(22):2314‐2324. [DOI] [PubMed] [Google Scholar]
- 2. Aoki V, Lorenzini D, Orfali RL, et al. Consensus on the therapeutic management of atopic dermatitis ‐ Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 suppl 1):67‐75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283‐289. [DOI] [PubMed] [Google Scholar]
- 4. Howell MD, Fitzsimons C, Smith PA. JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. Ann Allergy Asthma Immunol. 2018;120(4):367‐375. [DOI] [PubMed] [Google Scholar]
- 5. Liu LY, King BA. Tofacitinib for the treatment of severe alopecia areata in adults and adolescents. J Investig Dermatol Symp Proc. 2018;19(1):S18‐S20. [DOI] [PubMed] [Google Scholar]
- 6. Berbert Ferreira R, Ferreira SB, Scheinberg MA. An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature. Clin Case Rep. 2019;7(12):2539‐2542. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675.e1‐682.e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395‐399. [DOI] [PubMed] [Google Scholar]
- 9. Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902‐911. [DOI] [PubMed] [Google Scholar]
- 10. Renert‐Yuval Y, Guttman‐Yassky E. New treatments for atopic dermatitis targeting beyond IL‐4/IL‐13 cytokines. Ann Allergy Asthma Immunol. 2019;124(1):28‐35. [DOI] [PubMed] [Google Scholar]
- 11. Guttman‐Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate‐to‐severe atopic dermatitis: 16‐week results from a randomized, placebo‐ controlled trial. J Allergy Clin Immunol. 2019;145:877‐884. [DOI] [PubMed] [Google Scholar]
- 12. Simpson EL, Lacour J, Spelman L, et al. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomised monotherapy phase 3 trials. Br J Dermatol. 2020;183:242‐255. [DOI] [PubMed] [Google Scholar]
- 13. Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis. JAMA Dermatol. 2019;155(12):1371. [DOI] [PMC free article] [PubMed] [Google Scholar]